General Pharmacology — MCQs

General Pharmacology Indian Medical PG Practice Questions and MCQs

Question 71: First-order kinetics is characterized by:

A. Dose-independent elimination
B. Decreasing clearance as plasma concentration increases
C. Increasing rate of elimination as plasma concentration increases (Correct Answer)
D. No relationship between the rate of elimination and plasma concentration

Explanation: In **First-order kinetics** (linear kinetics), the rate of drug elimination is **directly proportional** to the plasma drug concentration. This is because the elimination systems (enzymes/transporters) are not saturated and can handle the increasing load. ### Why the correct answer is right: * **Option C:** In first-order kinetics, a **constant fraction** of the drug is eliminated per unit of time. As the plasma concentration increases, the absolute amount (rate) of drug being cleared also increases to maintain that constant fraction. Mathematically, $Rate = CL \times C$ (where $CL$ is clearance and $C$ is concentration). ### Why the other options are wrong: * **Option A:** First-order kinetics is **dose-dependent** regarding the rate of elimination. "Dose-independent" elimination describes Zero-order kinetics, where the rate remains constant regardless of concentration. * **Option B:** In first-order kinetics, **Clearance (CL) and Half-life ($t_{1/2}$)** remain **constant**. They do not change with plasma concentration. * **Option D:** There is a direct, linear relationship between the rate of elimination and plasma concentration. A lack of relationship defines Zero-order kinetics. ### High-Yield NEET-PG Pearls: 1. **Most drugs** follow first-order kinetics at therapeutic doses. 2. **Zero-order kinetics (Non-linear):** A constant *amount* is eliminated. Examples (Mnemonic: **WATT**): **W**arfarin, **A**lcohol/Aspirin, **T**heophylline, **T**olbutamide, and **P**henytoin. 3. **Steady State:** It takes approximately **4 to 5 half-lives** to reach steady-state concentration in first-order kinetics. 4. **Clearance Formula:** $CL = 0.693 \times Vd / t_{1/2}$. Since $CL$ and $Vd$ are constant in first-order, the $t_{1/2}$ is also constant.

Question 72: In which phase of clinical trials are micro-dosing studies typically conducted?

A. Phase 0 (Correct Answer)
B. Phase 1
C. Phase 2
D. Phase 3

Explanation: **Explanation:** **Phase 0** (also known as **Human Micro-dosing studies**) is the correct answer. These trials are conducted very early in the drug development process, often before traditional Phase 1 trials. The primary objective is to evaluate the **pharmacokinetics (PK) and pharmacodynamics (PD)** of a drug candidate in humans using sub-therapeutic doses (usually 1/100th of the calculated pharmacological dose). This helps researchers decide whether a drug should proceed to full-scale clinical development, thereby saving time and resources. **Why other options are incorrect:** * **Phase 1:** These are the first-in-human trials using therapeutic (escalating) doses. The primary goal is to determine **safety, tolerability, and the Maximum Tolerated Dose (MTD)** in a small group of healthy volunteers (except for oncology drugs). * **Phase 2:** These are "Proof of Concept" trials conducted on a small group of **patients** (100–300) to evaluate **efficacy** and determine the optimal dose range. * **Phase 3:** These are large-scale, multicentric, randomized controlled trials (RCTs) conducted on thousands of patients to confirm efficacy and compare the new drug against the current **standard of care**. **High-Yield Pearls for NEET-PG:** * **Phase 0** was introduced by the USFDA (2006) under the "Exploratory IND" (Investigational New Drug) guidance. * **Sample Size:** Very small (usually 10–15 subjects). * **Tool Used:** Highly sensitive analytical techniques like **Accelerator Mass Spectrometry (AMS)** are used to detect the minute concentrations of the drug in the blood. * **Phase 4:** Also known as **Post-Marketing Surveillance**, it is used to detect rare long-term adverse effects (e.g., Phocomelia with Thalidomide).

Question 73: In which phase of clinical trials are micro-dosing studies typically performed?

A. Phase 0 (Correct Answer)
B. Phase I
C. Phase II
D. Phase III

Explanation: **Explanation:** **Phase 0 clinical trials**, also known as **Human Micro-dosing studies**, are performed to bridge the gap between preclinical animal studies and Phase I human trials. 1. **Why Phase 0 is correct:** These studies involve the administration of a **sub-therapeutic dose** (usually 1/100th of the calculated pharmacological dose or <100 micrograms) to a small group of healthy volunteers (n=10-15). The primary objective is to evaluate **Pharmacokinetics (PK)** and **Pharmacodynamics (PD)**—specifically bioavailability and receptor affinity—without the risk of significant toxicity. This helps researchers decide early on whether a drug candidate has the desired properties to proceed to expensive Phase I trials. 2. **Why other options are incorrect:** * **Phase I:** Focuses on **Safety and Tolerability** (Maximum Tolerated Dose). It uses therapeutic (though escalating) doses in healthy volunteers. * **Phase II:** Focuses on **Therapeutic Efficacy** in a small group of actual patients. * **Phase III:** Focuses on **Comparative Efficacy** against a placebo or standard treatment in a large multicenter patient population. **High-Yield Clinical Pearls for NEET-PG:** * **Concept:** Phase 0 was introduced by the USFDA (2006) under the **Exploratory IND** (Investigational New Drug) guidance to reduce the "attrition rate" of drugs. * **Detection:** Since doses are minute, highly sensitive analytical techniques like **Accelerator Mass Spectrometry (AMS)** are used to measure drug levels. * **Limitation:** Phase 0 does **not** provide data on safety or efficacy. * **Sequence:** Preclinical $\rightarrow$ **Phase 0** $\rightarrow$ Phase I $\rightarrow$ Phase II $\rightarrow$ Phase III $\rightarrow$ NDA $\rightarrow$ Phase IV (Post-marketing surveillance).

Question 74: Azathioprine is used as what?

A. Immunosuppressant (Correct Answer)
B. Antigout drug
C. Antiretroviral
D. Anticancer agent

Explanation: **Explanation:** **Azathioprine** is a prodrug of **6-mercaptopurine (6-MP)**, which belongs to the class of purine antimetabolites. **1. Why Option A is Correct:** Azathioprine acts as a potent **immunosuppressant** by inhibiting purine synthesis (DNA/RNA synthesis). This primarily suppresses the proliferation of T and B lymphocytes, which are the drivers of the immune response. Clinically, it is used to prevent organ transplant rejection and to treat autoimmune conditions like Rheumatoid Arthritis, Systemic Lupus Erythematosus (SLE), and Inflammatory Bowel Disease (IBD). **2. Why Other Options are Incorrect:** * **B. Antigout drug:** While Azathioprine is related to purine metabolism, it is not used to treat gout. In fact, the antigout drug **Allopurinol** inhibits xanthine oxidase, the enzyme that metabolizes 6-MP. Co-administration leads to toxic levels of Azathioprine. * **C. Antiretroviral:** These drugs (e.g., Zidovudine) target viral enzymes like reverse transcriptase; Azathioprine has no antiviral activity. * **D. Anticancer agent:** Although its metabolite 6-MP is used in leukemia (ALL), Azathioprine itself is specifically optimized and clinically categorized as an immunosuppressant rather than a primary chemotherapeutic agent. **High-Yield NEET-PG Pearls:** * **Drug Interaction:** Always reduce the dose of Azathioprine by **1/4th to 1/3rd** if the patient is also taking **Allopurinol** to avoid life-threatening bone marrow suppression. * **Pharmacogenomics:** Deficiency of the enzyme **TPMT (Thiopurine Methyltransferase)** increases the risk of severe toxicity. * **Adverse Effect:** The most significant side effect is **bone marrow suppression** (pancytopenia).

Question 75: Variation in the sensitivity of a population of individuals to increasing doses of a drug is best determined by which of the following?

A. Efficacy
B. Potency
C. Therapeutic index
D. Quantal dose-response (Correct Answer)

Explanation: **Explanation:** The correct answer is **Quantal dose-response**. **1. Why Quantal Dose-Response is Correct:** A **Quantal dose-response curve** describes an "all-or-none" response (e.g., sleep vs. awake, alive vs. dead, relief of headache vs. no relief). Unlike a graded dose-response curve, which measures the intensity of effect in a single individual, the quantal curve plots the **cumulative frequency of individuals** in a population who exhibit a specific effect at increasing doses. Therefore, it is the primary tool used to determine **population variability** and sensitivity to a drug. **2. Why Other Options are Incorrect:** * **Efficacy (A):** Refers to the maximum effect ($E_{max}$) a drug can produce, regardless of dose. It relates to the drug's intrinsic activity, not population sensitivity. * **Potency (B):** Refers to the amount of drug (dose) required to produce an effect of a given intensity (usually measured as $EC_{50}$). While it compares drugs, it does not inherently measure population-wide sensitivity variation. * **Therapeutic Index (C):** This is a ratio ($TD_{50} / ED_{50}$) derived from quantal dose-response curves to measure drug safety. While it uses population data, it describes the safety margin rather than the variation in sensitivity itself. **High-Yield NEET-PG Pearls:** * **Graded Dose-Response:** Measures the *magnitude* of effect in an individual (determines $E_{max}$ and $EC_{50}$). * **Quantal Dose-Response:** Measures the *frequency* of effect in a population (determines $ED_{50}$, $TD_{50}$, and $LD_{50}$). * **Slope of Quantal Curve:** A steep slope indicates that most of the population responds within a narrow dose range (low variability), whereas a shallow slope indicates high individual variation in drug sensitivity.

Question 76: If a drug has a Volume of Distribution (Vd) equal to 60L, what does this indicate about the drug's distribution?

A. The drug is significantly sequestered in tissue sites. (Correct Answer)
B. The drug is highly bound to plasma proteins.
C. The drug is easily excreted.
D. None of the above.

Explanation: **Explanation:** The **Volume of Distribution (Vd)** is a theoretical volume that relates the total amount of drug in the body to its concentration in the plasma ($Vd = \text{Total amount of drug} / \text{Plasma concentration}$) [1]. In an average 70 kg adult, the total body water is approximately **42 liters** [1]. * **Plasma volume:** ~3-4 L [1] * **Extracellular fluid:** ~14 L [1] * **Total body water:** ~42 L [1] If a drug has a **Vd of 60L**, it exceeds the total body water (42L). This indicates that the drug is not confined to the plasma or extracellular fluid but has distributed extensively into the tissues [1]. A high Vd suggests the drug is **lipid-soluble** and is being **sequestered in tissue sites** (like fat, muscle, or specific organs), resulting in a very low plasma concentration [1]. **Analysis of Incorrect Options:** * **Option B:** High plasma protein binding keeps the drug confined to the vascular compartment, resulting in a **low Vd** (e.g., Warfarin, Vd ≈ 8L) [1]. * **Option C:** Vd relates to distribution, not directly to the rate of excretion. However, drugs with a high Vd are often harder to remove via hemodialysis because they are hidden in tissues rather than circulating in the blood. **NEET-PG High-Yield Pearls:** 1. **Low Vd (< 5L):** Drug is confined to plasma (e.g., Heparin). 2. **High Vd (> 42L):** Drug is sequestered in tissues (e.g., Digoxin, Chloroquine) [1]. **Chloroquine** has a massive Vd (~13,000L) due to high tissue binding [1]. 3. **Loading Dose Calculation:** $LD = Vd \times \text{Target Plasma Concentration}$. Drugs with high Vd require a higher loading dose to achieve therapeutic levels.

Question 77: Which of the following is an example of a covalent drug-receptor interaction?

A. Noradrenaline binding to the β1 adrenergic receptor
B. Acetylcholine binding to the muscarinic receptor
C. Prazosin binding to the α1 adrenergic receptor
D. Phenoxybenzamine binding to the alpha adrenergic receptor (Correct Answer)

Explanation: **Explanation:** The correct answer is **D. Phenoxybenzamine binding to the alpha adrenergic receptor.** **1. Why Phenoxybenzamine is Correct:** Most drug-receptor interactions are mediated by weak, reversible bonds (e.g., ionic, hydrogen, or Van der Waals). However, **Phenoxybenzamine** is a classic example of an **irreversible, non-competitive antagonist**. It undergoes a chemical transformation to form a highly reactive ethyleniminium intermediate, which then forms a **strong covalent bond** with the alpha-adrenergic receptor. Because covalent bonds are extremely stable, the blockade cannot be overcome by increasing the concentration of the agonist (like Noradrenaline). The effect lasts for 24–48 hours, as the body must synthesize new receptors to restore function. **2. Why the Other Options are Incorrect:** * **Options A & B (Noradrenaline and Acetylcholine):** These are endogenous neurotransmitters. Physiological signaling requires rapid onset and termination; therefore, these ligands bind via **reversible** (non-covalent) bonds to allow for quick dissociation. * **Option C (Prazosin):** Unlike phenoxybenzamine, Prazosin is a **selective, competitive** alpha-1 blocker. It binds via reversible ionic or hydrogen bonds, meaning its inhibitory effect can be reversed by increasing the concentration of an agonist. **3. High-Yield Clinical Pearls for NEET-PG:** * **Other Covalent/Irreversible Drugs:** Aspirin (COX inhibition), Omeprazole (Proton pump inhibition), Organophosphates (AChE inhibition), and Vigabatrin (GABA-transaminase inhibition). * **Clinical Use:** Phenoxybenzamine is primarily used in the preoperative management of **Pheochromocytoma** to prevent hypertensive crises. * **Key Concept:** Irreversible antagonists reduce the **Emax** (maximal efficacy) of an agonist on a dose-response curve, rather than just shifting the EC50.

Question 78: Respiratory center depression is caused by all the following, except?

A. Opium
B. Strychnine (Correct Answer)
C. Barbiturates
D. Gelsemium

Explanation: **Explanation:** The respiratory center in the medulla oblongata is highly sensitive to drugs that depress the Central Nervous System (CNS). **Why Strychnine is the correct answer:** Strychnine is a potent **CNS stimulant**, not a depressant. It acts as a competitive antagonist at **glycine receptors** (an inhibitory neurotransmitter) in the spinal cord and medulla. By blocking inhibition, it leads to unchecked neuronal excitation. Death from strychnine poisoning occurs due to **asphyxia** caused by continuous, violent spasms of the respiratory muscles (diaphragm and intercostals) and "opisthotonus," rather than depression of the respiratory center itself. **Analysis of other options:** * **Opium (Morphine):** Opioids are classic respiratory depressants. They act on $\mu$-receptors in the brainstem to reduce the responsiveness of the respiratory center to carbon dioxide ($CO_2$). * **Barbiturates:** These are sedative-hypnotics that enhance GABAergic inhibition. In high doses, they directly depress the medullary respiratory center and are a common cause of death in overdose. * **Gelsemium:** Derived from the "Yellow Jessamine" plant, it contains alkaloids (like gelsemine) that act as potent CNS depressants, leading to respiratory failure and paralysis. **High-Yield Clinical Pearls for NEET-PG:** * **Strychnine Poisoning:** Characterized by "Risus Sardonicus" (grimace) and spinal convulsions triggered by minimal sensory stimuli. The patient remains conscious until death. * **Antidote for Opioids:** Naloxone (pure antagonist). * **Drug of Choice for Strychnine Poisoning:** Intravenous Diazepam (to control convulsions) and maintaining a quiet environment. * **Cheyne-Stokes Respiration:** Can be seen in advanced opioid or barbiturate toxicity.

Question 79: Which of the following phase II drug metabolism reactions is associated with a genetic polymorphism?

A. Glucuronidation
B. Acetylation (Correct Answer)
C. Reduction
D. Oxidation

Explanation: **Explanation:** **Acetylation** is a major Phase II conjugation reaction catalyzed by the enzyme **N-acetyltransferase (NAT2)**. This enzyme exhibits a well-known **genetic polymorphism**, categorizing individuals into two distinct phenotypes: 1. **Fast Acetylators:** Metabolize drugs rapidly, potentially leading to sub-therapeutic levels. 2. **Slow Acetylators:** Metabolize drugs slowly, leading to higher plasma concentrations and an increased risk of toxicity. **Analysis of Options:** * **Acetylation (Correct):** It is the classic example of Phase II polymorphism. Drugs like **Isoniazid (INH), Hydralazine, Procainamide, and Dapsone** (remembered by the mnemonic **SHIP**) are metabolized this way. * **Glucuronidation (Incorrect):** While some polymorphisms exist (e.g., UGT1A1 in Gilbert’s syndrome), Acetylation is the primary high-yield answer for genetic polymorphism in Phase II reactions in the context of standard pharmacology exams. * **Oxidation and Reduction (Incorrect):** These are **Phase I reactions** (Functionalization), not Phase II (Conjugation). While Oxidation (via Cytochrome P450) shows significant polymorphism (e.g., CYP2D6), the question specifically asks for a Phase II reaction. **High-Yield Clinical Pearls for NEET-PG:** * **Drug-Induced Lupus Erythematosus (DILE):** Slow acetylators are at a significantly higher risk of developing DILE when taking Hydralazine or Procainamide. * **Peripheral Neuropathy:** Slow acetylators taking Isoniazid (INH) are more prone to Vitamin B6 deficiency and subsequent neuropathy. * **Bladder Cancer:** Slow acetylators have a higher risk of bladder cancer when exposed to environmental arylamines (e.g., cigarette smoke, industrial dyes).

Question 80: In which phase of clinical trials are healthy human volunteers typically included?

A. Phase I (Correct Answer)
B. Phase II
C. Phase III
D. Phase IV

Explanation: **Explanation:** **Phase I Clinical Trials** are primarily designed to assess the **safety, tolerability, and pharmacokinetics** of a new drug. This phase typically involves a small group (20–80) of **healthy human volunteers**. The goal is to determine the Maximum Tolerated Dose (MTD) and establish the safety profile before testing the drug in patients. *Exception:* In cases of highly toxic drugs (e.g., Cytotoxic Anticancer drugs), Phase I is conducted directly on patients rather than healthy volunteers. **Why other options are incorrect:** * **Phase II (Therapeutic Exploratory):** This phase is conducted on a small group of **actual patients** (100–300) to evaluate **efficacy** and determine the optimal dose-range. * **Phase III (Therapeutic Confirmatory):** This involves a large multicentric study on **patients** (1,000–3,000) to confirm efficacy and safety compared to the existing standard of care or placebo. * **Phase IV (Post-Marketing Surveillance):** This occurs **after** the drug is approved and marketed. It monitors long-term safety and identifies rare adverse effects in the general population. **High-Yield Clinical Pearls for NEET-PG:** * **Phase 0 (Microdosing):** Uses sub-therapeutic doses in humans to study pharmacokinetics; it precedes Phase I. * **"Human Pharmacology"** is another name for Phase I. * **Phase II** is the first phase where **efficacy** is measured (Proof of Concept). * **Phase III** is the most expensive and time-consuming phase. * **Teratogenicity** and rare side effects are usually detected in **Phase IV**.

Practice by Chapter

Pharmacokinetics: Absorption and Distribution

Practice Questions

Pharmacokinetics: Metabolism and Excretion

Practice Questions

Pharmacodynamics and Receptor Theory

Practice Questions

Drug-Receptor Interactions and Dose-Response

Practice Questions

Pharmacogenetics and Personalized Medicine

Practice Questions

Adverse Drug Reactions and Toxicity

Practice Questions

Drug Interactions

Practice Questions

Drug Development and Regulation

Practice Questions

Pediatric and Geriatric Pharmacology

Practice Questions

Placental Transfer and Lactation

Practice Questions

Want unlimited practice?

Get full access to all questions, explanations, and performance tracking.

Start For Free